Key Takeaways
- Choosing a dental practice broker can be one of the largest financial decisions in a dentist’s career. Three factors often matter most: a dental-only focus, sell-side-only representation, and a CPA-led valuation.
- Dental-specific experience can protect value because DSO buyers negotiate weekly while most sellers do so once. A broker without deep dental relationships often leaves money on the table.
- A diligence-grade valuation prepared by a CPA can prevent weak add-backs from being stripped during due diligence and can help protect the agreed price.
- Sell-side-only representation can reduce conflicts of interest. Brokers who also represent buyers or accept side payments may struggle to maximize seller outcomes.
- McLerran & Associates combines 35 years of dental-only experience, a structured 45- to 60-day auction process, and rigorous buyer vetting. This approach has historically produced roughly 30% higher valuations. Contact McLerran & Associates today to see what your practice may be worth.
Why Dental-Only, Sell-Side Experience Changes Your Outcome
A practice owner usually sells once in a lifetime. A dental service organization (DSO), which acquires and manages dental practices, negotiates deals every week. That experience gap creates a major information imbalance. The buyer arrives with data from hundreds of transactions, while the seller often has none.
A generalist broker who works across many healthcare niches usually cannot close that gap. Dental practice value can be shaped by specialty-specific buyer demand, regional market dynamics, payer mix, hygiene program strength, and provider concentration. These factors shift constantly and can differ sharply between an oral surgery group and a general practice. DSO buyers often prioritize regional density, provider continuity, and consistent operations, while private-equity-backed platforms focus on durable EBITDA and room for growth. A broker needs to understand these criteria in detail to position a practice correctly for each type of buyer.
Misreading these dynamics can have measurable consequences. The same practice can receive very different valuations depending on whether the buyer is a private individual or a DSO with strong strategic fit. A broker who lacks relationships across both buyer pools, or who knows only a few DSOs, usually leaves that valuation spread on the table.
McLerran & Associates has spent roughly 35 years focused exclusively on dental, evaluating more than 10,000 practices and closing approximately 2,000 transactions totaling around $2 billion in volume. This depth of dental-only experience allows the firm to read specialty-by-specialty and market-by-market trends rather than treating every practice the same. Buyers also tend to bid more aggressively on McLerran listings because they know the firm’s work product usually holds up under scrutiny.
How to Assess a Broker’s Valuation Approach
Valuation can be where most of the quiet damage in a dental practice sale occurs. A quick “free” number set by a buyer often becomes the anchor that shapes what the owner ultimately receives. A weak valuation analysis can then be dismantled during due diligence, which can force a lower price.
A credible valuation usually starts with adjusted EBITDA, which stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. In plain terms, EBITDA reflects the practice’s true operating profit before financing and accounting items. Adjusted EBITDA is calculated as reported EBITDA plus owner add-backs for discretionary, one-time, or non-operational expenses, minus normalized owner compensation at market replacement rates. For smaller solo practices, Seller’s Discretionary Earnings (SDE) can be more appropriate because it adds back the full owner compensation instead of replacing it with a market rate.
Add-backs are line items that inflate reported expenses but do not reflect the true cost of running the practice under new ownership. Dental-specific add-backs that buyers often accept include owner compensation above market, spouse payroll in administrative roles, owner health and malpractice insurance, one-time equipment purchases, and excess personal auto or phone expenses run through the practice. Add-backs that buyers usually reject, such as personal residence rent, cash payments not on the books, or family payroll far above market, should be removed before going to market. If they are not, buyers often strip them out during the quality-of-earnings review, which can reduce the price.
Aggressive or unsupportable add-backs are often the single most common reason a deal drops in price during due diligence. McLerran & Associates prepares a CPA-led, diligence-grade EBITDA analysis before any practice goes to market. This preparation helps the number hold when buyers review it and can reduce the risk of last-minute price cuts.
When you speak with potential brokers, ask direct questions. Who prepares your valuation, a CPA or a generalist analyst? How do you handle add-backs that a buyer’s quality-of-earnings team might challenge? How often have your valuations been re-traded in diligence, and what happened in those cases?
Questions That Reveal Dual-Agency and Fee Risks
Broker fee structures and representation models can create conflicts of interest that quietly cost sellers money. Before signing any engagement agreement, many owners find it helpful to ask several key questions directly.
Do you represent buyers as well as sellers? Dual agency, where one broker represents both sides of the same transaction, creates an inherent conflict. A broker cannot fully maximize the seller’s outcome and also protect the buyer’s negotiating position while being paid only if both parties agree to terms. McLerran & Associates works on the sell side only. The client is always the practice owner, not the buyer.
Do you accept referral fees or side compensation from buyers? Some brokers accept backdoor referral fees from buyers. This arrangement creates an incentive to steer sellers toward buyers who pay the broker more, rather than those who offer the strongest terms. The practice is legal but often not disclosed unless the seller asks. Many sellers choose to require written confirmation that the broker accepts no compensation from any buyer.
What does your tail clause cover? Listing agreements can include terms that keep sellers tied to a broker for a period, with holdover windows after expiration. During that time, a sale to any connected buyer can still trigger the full commission. Reputable firms usually provide a defined named-buyer list rather than an open-ended tail.
When does your fee trigger, at LOI or at close? Advisors who charge at Letter of Intent (LOI) signing instead of at closing can create misaligned incentives. Many sellers prefer that the fee be earned only when the deal actually closes and funds.
What is your actual commission structure? Most sell-side dental practice brokers charge an all-in commission of roughly 6% to 12% of final deal value. It can help to understand exactly what you are paying and which services that fee includes.
How a Structured Auction Process Builds Real Competition
A seller who speaks with only one buyer usually has little leverage, and buyers recognize this. The mechanism that often protects a seller’s valuation is competition among multiple qualified buyers, which requires a structured process rather than a single conversation.
McLerran & Associates runs an auction-style bid process for DSO and private-equity transactions. This process typically spans 45 to 60 days and generates around 10 offers per listing. It begins with a marketing deck and a virtual data room, which is a comprehensive, organized presentation of the practice, sent to a vetted pool of qualified buyers. Initial offers are collected, compared, and narrowed to the top one to three finalists. Those finalists then participate in in-person meetings or headquarters visits before a final offer is selected.
This competitive tension is not incidental. It is often the main force that lifts valuations. Running a competitive marketed process can add a premium on top of the usual DSO versus private-buyer spread. In 2026, practices that went to market through a structured multi-buyer process received final transaction values averaging 50% above initial unsolicited offers.
The quality of the buyer pool matters as much as the process itself. McLerran maintains a large premier private-buyer pool for doctor-to-doctor transactions and a pre-vetted DSO and private-equity buyer pool for corporate deals. Poorly run or undercapitalized buyers are removed from this pool before they ever reach a seller. As of mid-2026, roughly 130 PE-backed DSOs were active in dental practice acquisitions, which is a scale that an individual seller would struggle to access alone.
As a result, McLerran clients often see around a 30% increase in valuation compared to selling on their own. The firm reports a transaction close rate of roughly 85% to 90%, compared to an industry norm closer to 35% to 40%.
Side-by-Side Economics for Private Buyers and DSOs
The table below compares four approaches to selling a dental practice across several dimensions that can shape a seller’s outcome. Every figure is drawn from available market data and McLerran’s documented track record.
| Dimension | DIY / For-Sale-by-Owner | Local Generalist Broker | Multi-Vertical Advisor | McLerran & Associates |
|---|---|---|---|---|
| Dental specialization | None | Local only; limited specialty depth | Spread across multiple healthcare verticals | Dental-only, national, 35-year track record |
| Both sale pathways (private buyer + DSO) | No | Usually one pathway | Sometimes | Both, approximately 50/50 split |
| Valuation quality | Buyer-set anchor; no independent analysis | Variable; often limited add-back analysis | Variable; may lack dental-specific normalization | CPA-led, diligence-grade; defended through quality-of-earnings review |
| Competitive offers generated | 1 (no competition) | Minimal; 1–2 DSO relationships | Some; limited dental buyer pool depth | ~10 offers per listing; roughly 130 PE-backed DSOs active in the market |
| Transaction (close) rate | ~15–20% | Below industry average | Variable | ~85–90% vs. industry norm of ~35–40% |
| Valuation lift vs. going alone | Baseline (0%) | Modest | Variable | ~30% higher on average; structured process adds premium above DSO-private buyer spread |
| Process timeline (DSO path) | Undefined; buyer-controlled | Variable | Variable | ~45–60-day structured bid process |
| Sell-side only | N/A | Not always | Not always | Always; never represents buyers |
The economics of the two sale pathways also differ in meaningful ways. DSOs can often pay more than individual private buyers for the same dollar of earnings when the practice meets their platform-fit criteria. This difference becomes especially important for practices in the $1.5 million to $3 million revenue range, where both pathways may be viable options and the valuation gap between them can be significant. A side-by-side valuation from a broker who works both markets is usually the only way to quantify that gap with real numbers instead of guesswork.
How Buyer Vetting Protects Your Staff, Patients, and Legacy
The highest bidder is not always the right buyer. Many practice owners who have spent decades building relationships with patients and staff care deeply about what happens to those people after the sale. A broker who focuses only on headline price can put that legacy at risk.
Buyer vetting usually operates on two levels. The first level is financial. Buyers can be assessed across valuation capacity, structural complexity, diligence depth, transition expectations, and certainty of close. A DSO that cannot close without heavy contingencies, or one with weak private-equity backing, represents a real risk. Up to 40% of a DSO deal can be paid in equity rather than cash, which means the seller becomes an investor in that DSO and may want to evaluate it carefully.
The second level is operational and cultural. Many sellers want to know whether the buyer has a track record of retaining staff and maintaining clinical standards after acquisition. DSOs are increasingly requiring a minimum 5-year post-close employment term from sellers and often view provider risk and clinical continuity issues as top reasons for walking away from deals. The seller’s post-close experience has become a material part of the transaction, not an afterthought.
McLerran & Associates screens buyers before they ever reach a seller. Poorly run DSOs, including those known for difficult post-close environments or those that struggled after capital flooded the space, are removed from consideration. The firm’s mandate is to balance price and fit, aiming for a strong financial outcome while identifying a buyer whose strategy and support model align with the owner’s goals for the practice.
For doctor-to-doctor transactions, McLerran serves as a buffer between seller and buyer throughout the process. This role can help protect staff relationships and goodwill during what is often an emotional transition.
placeholder
Frequently Asked Questions
How do I know whether to sell to a private buyer or a DSO?
The right pathway can depend on your practice’s size, profitability, and your personal goals. Smaller premier practices, generally in the $1 million to $1.5 million revenue range, often fit a doctor-to-doctor sale where another dentist takes over the practice and its goodwill. Larger practices, particularly those above $1.5 million in revenue, may be well suited for a DSO affiliation, which can offer a higher total valuation because DSOs use EBITDA-based multiples that tend to exceed the revenue-based or SDE-based multiples used in private-buyer deals. Practices in the middle range can often go either direction. Because McLerran works both markets in roughly equal measure, the firm can produce a side-by-side valuation that quantifies what your practice may be worth on each path so you can choose with more complete information.
What is the difference between EBITDA and Seller’s Discretionary Earnings, and which one applies to my practice?
EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is the standard measure used by DSOs and private-equity buyers. It reflects the practice’s operating profit after replacing the owner’s compensation with a market-rate cost for a clinical replacement, which approximates what the business earns under professional management. Seller’s Discretionary Earnings (SDE) adds back the full owner compensation instead of replacing it, which produces a larger earnings number that reflects the total financial benefit available to a single owner-operator. SDE is typically used for smaller solo practices sold to individual dentists using bank financing. The right measure can depend on your practice’s size and likely buyer type, which is one reason a CPA-led valuation that applies the correct methodology can matter.
How long does the process typically take, and when should I start?
For a DSO or private-equity transaction, McLerran’s structured bid process typically runs 45 to 60 days from going to market to receiving offers, followed by additional time for due diligence, negotiation, and closing. Doctor-to-doctor transactions vary based on buyer financing and transition structure. The full journey from first conversation to closed deal commonly takes several months. Many owners find that the best time to start is before they feel urgency, because practices that go to market under time pressure often have less negotiating leverage. If you are not ready to sell, McLerran can complete a valuation and update it for free a year later so you have a current number when you are ready. Demand for premier practices remains strong and valuations sit near all-time highs as of mid-2026, although market conditions can change and preparation takes time.
How much of a DSO deal is paid in cash versus equity?
DSO offers are almost always a mix of cash at close, equity in the DSO, and sometimes an earnout, which is a portion of the payment tied to future performance targets. Cash at close commonly represents 60% to 85% or more of the total consideration, although the exact split varies by buyer and structure. The equity portion, which can represent up to roughly 40% of total deal value, can be held at the joint-venture level with ongoing distributions and a higher floor but lower ceiling, or at the holding-company level with no distributions but potential for a larger payout if the DSO is recapitalized or sold. Because a significant share of your proceeds may depend on the DSO’s future performance, evaluating the buyer’s financial health, management team, and private-equity backing can be just as important as negotiating the headline number. McLerran prepares multi-year financial forecasts across deal structures so you can compare what each offer may be worth over time.
Why does McLerran charge for its valuation when other firms offer free valuations?
A free valuation usually serves as a lead-generation tool, not as a diligence-grade analysis. It often produces a quick number designed to start a conversation rather than a figure that can withstand buyer scrutiny. When a buyer’s quality-of-earnings team reviews the financials during due diligence, a weak valuation can be challenged, add-backs can be removed, and the agreed price can be renegotiated downward. McLerran’s CPA-led valuation is designed as diligence-grade work completed before the practice goes to market, the kind of analysis that tends to hold up when buyers examine the details and that most accountants would recognize as rigorous. The cost of this level of valuation is usually small compared to the value it can protect. In one documented case, a free valuation placed a practice at $2.5 million. McLerran’s analysis valued it at $4.5 million, and it sold for $5.25 million after a competitive process. The firm’s position is straightforward: it aims to sell practices, not simply list them.
